Drug Search Results
Using advanced filters...
Advanced Search [+]

Semapimod

Alternative Names: semapimod
Latest Update: 2024-12-10
Latest Update Note: News Article

Product Description

Mechanisms of Action: MAP2K Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Ferring
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Crohn Disease

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Semapimod

P1

Completed

Crohn Disease

2009-10-01

CD06

P2

Completed

Crohn Disease

2006-06-01

CD05

P2

Completed

Crohn Disease

2004-07-01

CD04

P2

Completed

Crohn Disease

2004-06-01

24%

Recent News Events